BeOne Medicines Ltd
Company Profile
Business description
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.
Contact
c/o BeOne Medicines I GmbH
94 Aeschengraben 27
21st Floor
Basel4051
CHET: +41 616851900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
12,000
Stocks News & Analysis
stocks
This ASX supermarkets business is now underperforming its largest competitor
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,886.60 | 14.50 | 0.16% |
| CAC 40 | 7,976.12 | 138.72 | -1.71% |
| DAX 40 | 23,991.27 | 301.11 | -1.24% |
| Dow JONES (US) | 48,941.90 | 557.37 | -1.13% |
| FTSE 100 | 10,363.93 | 14.89 | -0.14% |
| HKSE | 25,736.54 | 359.34 | -1.38% |
| NASDAQ | 25,067.80 | 46.64 | -0.19% |
| Nikkei 225 | 59,513.12 | 228.20 | 0.38% |
| NZX 50 Index | 13,035.70 | 61.98 | -0.47% |
| S&P 500 | 7,200.75 | 29.37 | -0.41% |
| S&P/ASX 200 | 8,661.80 | 20.10 | 0.23% |
| SSE Composite Index | 4,112.16 | 4.65 | 0.11% |